Aeglea BioTherapeutics: Enzyme Replacement Therapy

Aeglea BioTherapeutics is in the process of developing an enzyme replacement therapy for patients with CBS Deficiency Homocystinuria.
For the most up-to-date news on their enzyme replacement, please visit their website: Click here

October 10, 2018

Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting

Positive Preclinical Efficacy Data on its AEB4104 Homocystinuria Therapeutic Program

July 30, 2018

Aeglea BioTherapeutics Announces Fall 2018 Medical Conference Schedule

Preclinical Efficacy Data of AEB4104 - a New Enzyme Approach - for the treatment of Homocystinuria